Paolo F. Caimi

Paolo F. Caimi

Hematology Oncology | Hematology | Oncology
9500 Euclid Avenue
Cleveland, OH 44195

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 159 publications

Step-Specific Activation Timelines for Cellular Therapy Clinical Trials: A Decade of Regulatory Improvement and Persistent Financial Bottlenecks.

Step-Specific Activation Timelines for Cellular Therapy Clinical Trials: A Decade of Regulatory Improvement and Persistent Financial Bottlenecks.

Journal: Transplantation and cellular therapy
Published: April 20, 2026

Neighborhood Socioeconomic Disadvantage and Distance From Treatment Center do not Impact Survival Outcomes of Patients With Non-Hodgkin Lymphoma and Multiple Myeloma Treated With CAR T-Cell Therapies.

Neighborhood Socioeconomic Disadvantage and Distance From Treatment Center do not Impact Survival Outcomes of Patients With Non-Hodgkin Lymphoma and Multiple Myeloma Treated With CAR T-Cell Therapies.

Journal: Transplantation and cellular therapy
Published: April 17, 2026

B-cell activating factor plays a critical role in CAR-T cell-associated cytokine release syndrome.

B-cell activating factor plays a critical role in CAR-T cell-associated cytokine release syndrome.

Journal: bioRxiv : the preprint server for biology
Published: December 17, 2025

NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.

NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: October 09, 2025

Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma.

Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma.

Journal: Leukemia
Published: September 02, 2025

Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study.

Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study.

Journal: Leukemia & lymphoma
Published: May 21, 2025

Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure.

Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure.

Journal: HemaSphere
Published: May 06, 2025

CAR T-cell reality for R/R LBCL: challenges and challengers.

CAR T-cell reality for R/R LBCL: challenges and challengers.

Journal: Blood advances
Published: March 11, 2025

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.

Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab.

Journal: Blood
Published: March 06, 2025

Disparities in real-world treatment patterns of hypomethylating agents among patients with MDS in the United States.

Disparities in real-world treatment patterns of hypomethylating agents among patients with MDS in the United States.

Journal: Blood neoplasia
Published: January 15, 2025

Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.

Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.

Journal: Blood advances
Published: December 10, 2024

Loncastuximab tesirine in previously treated diffuse large B-cell lymphoma: A plain language summary of the LOTIS-2 study.

Loncastuximab tesirine in previously treated diffuse large B-cell lymphoma: A plain language summary of the LOTIS-2 study.

Journal: Future oncology (London, England)
Published: November 12, 2024
Showing 1-12 of 159

Last Updated: 09/26/2026